Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Here's Why Becton Dickinson (BDX) is a Strong Growth Stock

In This Article:

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.

Becton Dickinson (BDX)

Based in Franklin Lakes, NJ, Becton, Dickinson and Company, commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.

BDX is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 9.8% year-over-year for the current fiscal year, with sales growth of 8.3%.

Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0 to $14.43 per share. BDX boasts an average earnings surprise of 7.3%.

On a historic basis, Becton Dickinson has generated cash flow growth of 1.7%, and is expected to report cash flow expansion of 4.2% this year.

With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, BDX should be on investors' short lists.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Becton, Dickinson and Company (BDX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research